Advertisement

Treatment of Dystonic Pain with Botulinum Neurotoxins

  • Bahman Jabbari
Chapter
  • 705 Downloads

Abstract

Focal dystonia is a common neurological disorder which is often painful. This chapter reviews clinical features of three common and painful focal dystonias, namely, cervical dystonia, focal dystonia associated with neurodegenerative disorders, and post-traumatic dystonia. The literature on the efficacy of botulinum toxins for these three forms of dystonic pain is reviewed. Fourteen blinded and placebo-controlled clinical trials assessed pain at baseline and after BoNT treatment of cervical dystonia. All 14 reported efficacy against pain. CD-related pain responded also to all three types of A neurotoxins as well as the type B neurotoxin. Small retrospective studies and clinical observations demonstrate that currently available neurotoxins (A or B) improve pain of Parkinson-related dystonias (toe flexion and foot inversion) as well as painful post-traumatic dystonias. Blinded studies for these indications are not available. Case reports and short videotape clips from author’s experience are provided to demonstrate patients’ histories and the technique of BoNT administration.

Keywords

Cervical dystonia Dystonic pain Parkinson’s disease Atypical Parkinson disorders Post-traumatic dystonia Pain Botulinum toxin Botulinum neurotoxin OnabotulinumtoxinA (onaA) AbobotulinumtoxinA (aboA) IncobotulinumtoxinA (incoA) RimabotulinumtoxinB (rimaB) 

Supplementary material

Video 12.1

EMG-guided injections of flexor digitorum brevis and flexor hallucis of the foot in a patient with painful toe flexion dystonia (MOV 22556 kb)

Video 12.2

Left tibialis posterior injection (EMG guided) in a patient with probable CBD and painful foot inversion dystonia (Case 12-2) (MPG 5299 kb)

References

  1. Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, Hallett M, Jankovic J, Jinnah HA, Klein C, Lang AE, Mink JW, Teller JK. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28:863–73.CrossRefPubMedCentralPubMedGoogle Scholar
  2. Armstrong MJ. Diagnosis and treatment of corticobasal degeneration. Curr Treat Options Neurol. 2014;16:282.CrossRefPubMedGoogle Scholar
  3. Brans JW, Linderboom R, Snoek JW, Zwarts MJ, van Weerden TW, Brunt ER, van Hilten JJ, van der Kamp W, Prins MH, Speelman JD. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind trial. Neurology. 1996;46:1066–72.CrossRefPubMedGoogle Scholar
  4. Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, Trosch R, Singer C, Brin MF, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999;53:1439–46.CrossRefPubMedGoogle Scholar
  5. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O’Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53:1431–8.CrossRefPubMedGoogle Scholar
  6. Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord. 1991;6:119–26.CrossRefPubMedGoogle Scholar
  7. Charles D, Brashear A, Hauser RA, Li HI, Boo LM, Brin MF, CD 140 Study Group. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol. 2012;35:208–14.CrossRefPubMedGoogle Scholar
  8. Charles PD, Adler CH, Stacy M, Comella C, Jankovic J, Manack Adams A, Schwartz M, Brin MF. Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of onabotulinumtoxinA Efficacy). Neurology. 2014;261:1309–19.CrossRefGoogle Scholar
  9. Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, Fan W, Dystonia Study Group. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005;65:1423–9.CrossRefPubMedGoogle Scholar
  10. Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S, U.S. XEOMIN Cervical Dystonia Study Group. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011;308:103–9.CrossRefPubMedGoogle Scholar
  11. Cordivari C, Misra VP, Catania S, Lees AJ. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord. 2001;16:907–13.CrossRefPubMedGoogle Scholar
  12. Duarte J, Sempere AP, Coria F, Claveria LE, Frech FA, Mataix AL, Martinez E. Isolated idiopathic adult-onset foot dystonia and treatment with botulinum toxin. J Neurol. 1995;242:114–5.CrossRefPubMedGoogle Scholar
  13. Fernandez HH, Pappert EJ, Comella CL, Evidente VG, Truong DD, Verma A, Jankovic J. Efficacy and safety of incobotulinumtoxinA in subjects previously treated with botulinum toxin versus toxin-naïve subjects with cervical dystonia. Tremor Other Hyperkinet Mov (N Y). 2013;3. pii: tre-03-140-2921-1. Print 2013.Google Scholar
  14. Fuchs T, Saunders-Pullman R, Masuho I, Luciano MS, Raymond D, Factor S, Lang AE, Liang TW, Trosch RM, White S, Ainehsazan E, Hervé D, Sharma N, Ehrlich ME, Martemyanov KA, Bressman SB, Ozelius LJ. Mutations in GNAL cause primary torsion dystonia. Nat Genet. 2013;45:88–92.CrossRefPubMedCentralPubMedGoogle Scholar
  15. Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology. 1990;40:1213–8.CrossRefPubMedGoogle Scholar
  16. Ha AD, Jankovic J. Pain in Parkinson’s disease. Mov Disord. 2012;27:485–91.CrossRefPubMedGoogle Scholar
  17. Jankovic J. Treatment of cervical dystonia with botulinum toxin. Mov Disord. 2004;19 Suppl 8:S109–15.CrossRefPubMedGoogle Scholar
  18. Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology. 1990;40:277–80.CrossRefPubMedGoogle Scholar
  19. Jankovic J, Tintner R. Dystonia and parkinsonism. Parkinsonism Relat Disord. 2001;8:109–21.CrossRefPubMedGoogle Scholar
  20. Jankovic J, Leder S, Warner D, Schwartz K. Cervical dystonia: clinical findings and associated movement disorders. Neurology. 1991;41:1088–91.CrossRefPubMedGoogle Scholar
  21. Kaji R, Shimizu H, Takase T, Osawa M, Yanagisawa N. A double-blind comparative study to evaluate the efficacy and safety of NerBloc® (rimabotulinumtoxinB) administered in a single dose to patients with cervical dystonia. Brain Nerve. 2013;65:203–11.PubMedGoogle Scholar
  22. Laubis-Herrmann U, Fries K, Topka H. Low-dose botulinum toxin-a treatment of cervical dystonia – a double-blind, randomized pilot study. Eur Neurol. 2002;47:214–21.CrossRefPubMedGoogle Scholar
  23. Lew MF, Adornato BT, Duane DD, Dykstra DD, Factor SA, Massey JM, Brin MF, Jankovic J, Rodnitzky RL, Singer C, Swenson MR, Tarsy D, Murray JJ, Koller M, Wallace JD. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology. 1997;49:701–7.CrossRefPubMedGoogle Scholar
  24. Lew MF, Chinnapongse R, Zhang Y, Corliss M. RimabotulinumtoxinB effects on pain associated with cervical dystonia: results of placebo and comparator-controlled studies. Int J Neurosci. 2010;120:298–300.CrossRefPubMedGoogle Scholar
  25. LeWitt PA, Burns RS, Newman RP. Dystonia in untreated parkinsonism. Clin Neuropharmacol. 1986;9:293–7.CrossRefPubMedGoogle Scholar
  26. Lorentz IT, Subramaniam SS, Yiannikas C. Treatment of idiopathic spasmodic torticollis with botulinum toxin A: a double-blind study on twenty-three patients. Mov Disord. 1991;6:145–50.CrossRefPubMedGoogle Scholar
  27. Marsh WA, Monroe DM, Brin MF, Gallagher CJ. Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia. BMC Neurol. 2014;14:91.CrossRefPubMedCentralPubMedGoogle Scholar
  28. McKeon A, Matsumoto JY, Bower JH, Ahlskog JE. The spectrum of disorders presenting as adult-onset focal lower extremity dystonia. Parkinsonism Relat Disord. 2008;14:613–9.CrossRefPubMedGoogle Scholar
  29. Müller J, Wenning GK, Wissel J, Seppi K, Poewe W. Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. J Neurol. 2002;249:300–4.CrossRefPubMedGoogle Scholar
  30. Nutt JG, Muenter MD, Aronson A, Kurland LT, Melton LJ. Epidemiology of focal and generalized dystonia in Rochester, 1968567-603. Minn Mov Disord. 1988;3:188–94.CrossRefGoogle Scholar
  31. Pacchetti C, Albani G, Martignoni E, Godi L, Alfonsi E, Nappi G. ‘Off’ painful dystonia in Parkinson’s disease treated with botulinum toxin. Mov Disord. 1995;10:333–6.CrossRefPubMedGoogle Scholar
  32. Pappert EJ, Germanson T, Myobloc/Neurobloc European Cervical Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord. 2008;15(23):510–7.CrossRefGoogle Scholar
  33. Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R, Kessler KR, Ceballos-Baumann AO, Ohly A, Oertel W, Künig G. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry. 1998;64:13–7.CrossRefPubMedCentralPubMedGoogle Scholar
  34. Quagliato EM, Carelli EF, Viana MA. A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia. Clin Neuropharmacol. 2010;33:22–6.PubMedGoogle Scholar
  35. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry. 2002;72:459–62.PubMedCentralPubMedGoogle Scholar
  36. Sheffield JK, Jankovic J. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson’s disease. Expert Rev Neurother. 2007;7:637–47.CrossRefPubMedGoogle Scholar
  37. Singer C, Papapetropoulos S. Adult-onset primary focal foot dystonia. Parkinsonism Relat Disord. 2006;12:57–60.CrossRefPubMedGoogle Scholar
  38. Skogseid IM. Dystonia-new advances in classification, genetics, pathophysiology and treatment. Acta Neurol Scand Suppl. 2014;198:13–9.CrossRefPubMedGoogle Scholar
  39. Steeves TD, Day L, Dykeman J, Jette N, Pringsheim T. The prevalence of primary dystonia: a systematic review and meta-analysis. Mov Disord. 2012;27:1789–96.CrossRefPubMedGoogle Scholar
  40. Tassorelli C, Mancini F, Balloni L, Pacchetti C, Sandrini G, Nappi G, Martignoni E. Botulinum toxin and neuromotor rehabilitation: an integrated approach to idiopathic cervical dystonia. Mov Disord. 2006;21:2240–3.CrossRefPubMedGoogle Scholar
  41. Tinazzi M, Del Vesco C, Fincati E, Ottaviani S, Smania N, Moretto G, Fiaschi A, Martino D, Defazio G. Pain and motor complications in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2006;77:822–5.CrossRefPubMedCentralPubMedGoogle Scholar
  42. Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, Lew MF, Rodnitzky RL, Danisi FO, Sutton JP, Charles PD, Hauser RA, Sheean GL. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005;20:783–91.CrossRefPubMedGoogle Scholar
  43. Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, Orlova O, Timerbaeva S, Global Dysport Cervical Dystonia Study Group. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010;16:316–23.CrossRefPubMedGoogle Scholar
  44. Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet. 1986;2:245–7.CrossRefPubMedGoogle Scholar
  45. Walsh RA, Sidiropoulos C, Lozano AM, Hodaie M, Poon YY, Fallis M, Moro E. Bilateral pallidal stimulation in cervical dystonia: blinded evidence of benefit beyond 5 years. Brain. 2013;136:761–9.CrossRefPubMedGoogle Scholar
  46. Wasner G, Deuschl G. Pains in Parkinson disease – many syndromes under one umbrella. Nat Rev Neurol. 2012;8:284–94.CrossRefPubMedGoogle Scholar
  47. Wissel J, Kanovsky P, Ruzicka E, Bares M, Hortova H, Streitova H, Jech R, Roth J, Brenneis C, Müller J, Schnider P, Auff E, Richardson A, Poewe W. Efficacy and safety of a standardized 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel group study. J Neurol. 2001;248:1073–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Bahman Jabbari
    • 1
  1. 1.Botulinum Toxin Treatment ProgramYale School of MedicineNew HavenUSA

Personalised recommendations